AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38102687 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone intravenous bolus over 5 minutes
Number of subjects: 378
Study 38102687 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 378
Study 38103056 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II
Number of subjects: 81
Study 38103056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 38103088 — intervention group
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa
Number of subjects: 122
Study 38103088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 38103144 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 84
Study 38103144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 38103161 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCOV 20 µg
Number of subjects: 447
Study 38103161 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCOV 40 µg
Number of subjects: 447
Study 38103161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 38103359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 126
Study 38103359 — intervention group
Group type: COMPARATOR
Intervention: Stress Management Training (SMT)
Number of subjects: 126
Study 38103438 — intervention group
Group type: EXPERIMENTAL
Intervention: Deinstitutionalization intervention
Number of subjects: 241
Study 38103462 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lacticaseibacillus rhamnosus GG (LGG)
Number of subjects: 182
Study 38103462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 38103646 — intervention group
Group type: EXPERIMENTAL
Intervention: Free amino acids
Number of subjects: 16
Study 38103646 — intervention group
Group type: COMPARATOR
Intervention: Intact protein
Number of subjects: 16
Study 38103784 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based intervention (YBI) with personal practice videos, private sessions, daily text messages, and monetary incentives
Number of subjects: 192
Study 38103842 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat 100 mg 3 times daily
Number of subjects: 264
Study 38103842 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat 200 mg 3 times daily
Number of subjects: 264
Study 38103842 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat 300 mg 3 times daily
Number of subjects: 264
Study 38103842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 38103896 — intervention group
Group type: EXPERIMENTAL
Intervention: Working conditions and health access
Number of subjects: 539
Study 38103896 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health status
Number of subjects: 539
Study 38103896 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to zoonoses and heavy metal poisoning
Number of subjects: 539
Study 38103913 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early invasive strategy (IS)
Number of subjects: 425
Study 38103913 — intervention group
Group type: COMPARATOR
Intervention: Standard care invasive strategy (IS)
Number of subjects: 425
Study 38103947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg (DL 0) or 40 mg (DL 1) daily on days 1-28 combined with FTD/TPI 35 mg/m².
Number of subjects: 15
Study 38103947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib and FTD/TPI combination treatment.
Number of subjects: 15
Study 38103956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil beam scanning proton therapy with a simultaneous integrated boost (SIB) approach and at least 1 rescan evaluation during the first 5 ± 2 fractions.
Number of subjects: 42
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (first-line treatment, 69.9% of patients)
Number of subjects: 1882
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (18.6% of patients)
Number of subjects: 1882
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (4.7% of patients)
Number of subjects: 1882
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: General TKI treatment adherence
Number of subjects: 1882
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free remission (TFR)
Number of subjects: 1882
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health concerns
Number of subjects: 1882
Study 38104036 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of COVID-19 on treatment
Number of subjects: 1882
Study 38104131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (administered orally 6-12 hours prior to prostate biopsy)
Number of subjects: 30
Study 38104131 — intervention group
Group type: COMPARATOR
Intervention: Placebo standard-of-care (with all patients receiving definitive brachytherapy)
Number of subjects: 30
Study 38104145 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive opioid-sparing analgesic protocol
Number of subjects: 33
Study 38104145 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 33
Study 38104476 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38104538 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anuric participants (cumulative 24 h UO at inclusion ≥0.05 mL kg-1 h-1)
Number of subjects: 42
Study 38104538 — intervention group
Group type: COMPARATOR
Intervention: Anuric participants (cumulative 24 h UO at inclusion <0.05 mL kg-1 h-1)
Number of subjects: 42
Study 38104538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher UFNET flow rates
Number of subjects: 42
Study 38104538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower UO
Number of subjects: 42
Study 38104538 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher UFNET
Number of subjects: 42
Study 38104569 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 200→100 mg
Number of subjects: 309
Study 38104569 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 600→200 mg
Number of subjects: 309
Study 38104569 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 1200→200 mg
Number of subjects: 309
Study 38104569 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 309
Study 38104569 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 309
Study 38104575 — intervention group
Group type: EXPERIMENTAL
Intervention: KarXT (xanomeline-trospium)
Number of subjects: 252
Study 38104575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 38104577 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT plus standard of care
Number of subjects: 106
Study 38104577 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 106
Study 38104577 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT plus standard of care (NSCLC subgroup)
Number of subjects: 106
Study 38104577 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (NSCLC subgroup)
Number of subjects: 106
Study 38104577 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT plus standard of care (breast cancer subgroup)
Number of subjects: 106
Study 38104577 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (breast cancer subgroup)
Number of subjects: 106
Study 38104755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus azithromycin
Number of subjects: 1114
Study 38104755 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine alone
Number of subjects: 1114
Study 38104857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive body weight management program with intermittent fasting (IF)
Number of subjects: 154
Study 38104857 — intervention group
Group type: COMPARATOR
Intervention: Intensive body weight management program without intermittent fasting (IF)
Number of subjects: 154
Study 38104937 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11000
Study 38104937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11000
Study 38104943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 1.5 h/night
Number of subjects: 26
Study 38104943 — intervention group
Group type: COMPARATOR
Intervention: Adequate Sleep (AS) - ≥7 h sleep/night
Number of subjects: 26
Study 38105142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib (120 mg QD or 100 mg QD) plus Nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks)
Number of subjects: 244
Study 38105142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib plus Nivolumab
Number of subjects: 244
Study 38105176 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-assisted risk disclosure (direct letters to at-risk relatives)
Number of subjects: 0
Study 38105176 — intervention group
Group type: COMPARATOR
Intervention: Standard care (family-mediated risk disclosure)
Number of subjects: 0
Study 38105505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab (2, 8, 30, 100, 400, 600, or 1200 mg) followed by atezolizumab (1200 mg)
Number of subjects: 0
Study 38105505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab (840 mg) followed by atezolizumab (1680 mg)
Number of subjects: 0
Study 38105505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab (840 mg) plus atezolizumab (1680 mg)
Number of subjects: 0
Study 38105538 — intervention group
Group type: EXPERIMENTAL
Intervention: ERβ transfection in LAR TNBC cell lines
Number of subjects: 146
Study 38105538 — intervention group
Group type: COMPARATOR
Intervention: AR
Number of subjects: 146
Study 38105538 — intervention group
Group type: EXPERIMENTAL
Intervention: NECTIN4 promoter interaction with AR
Number of subjects: 146
Study 38105655 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 30
Study 38105847 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM V pattern plate with surgical guide
Number of subjects: 26
Study 38105847 — intervention group
Group type: COMPARATOR
Intervention: Standard superior-inferior miniplate fixation
Number of subjects: 26
Study 38105911 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% reproxalap ophthalmic solution
Number of subjects: 95
Study 38105911 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 95
Study 38105936 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices collecting physiological parameters
Number of subjects: 550
Study 38105958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + Capecitabine
Number of subjects: 45
Study 38105958 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 45
Study 38105958 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 45
Study 38106014 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise 3-4 minute animated video for patient education prior to TGT
Number of subjects: 150
Study 38106133 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-driven guidance of antiplatelet therapy
Number of subjects: 0
Study 38106133 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 38106151 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, lenalidomide, and dexamethasone (Dara-Rd)
Number of subjects: 32
Study 38106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered music
Number of subjects: 432
Study 38106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered reading
Number of subjects: 432
Study 38106552 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 432
Study 38106555 — intervention group
Group type: EXPERIMENTAL
Intervention: Zapnometinib (900 mg on Day 1; 600 mg on Days 2-6)
Number of subjects: 104
Study 38106555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 38106555 — intervention group
Group type: EXPERIMENTAL
Intervention: Zapnometinib
Number of subjects: 104
Study 38106559 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 10171
Study 38106559 — intervention group
Group type: EXPERIMENTAL
Intervention: non-COVID-19 ARI
Number of subjects: 10171
Study 38106559 — intervention group
Group type: COMPARATOR
Intervention: No infection
Number of subjects: 10171
Study 38106561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus nab-paclitaxel
Number of subjects: 27
Study 38106564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting bioadaptor
Number of subjects: 445
Study 38106564 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting drug-eluting stent
Number of subjects: 445
Study 38106570 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (10-100 mg for days 1-21, 200 mg for days 22-84)
Number of subjects: 27
Study 38106570 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 27
Study 38106893 — intervention group
Group type: EXPERIMENTAL
Intervention: Data to Care (D2C) model
Number of subjects: 0
Study 38106904 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app promoting physical activity (PA) and an active healthy lifestyle
Number of subjects: 0
Study 38106904 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app features developed through cocreation sessions
Number of subjects: 0
Study 38106904 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative design thinking approach
Number of subjects: 0
Study 38106904 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app implementation
Number of subjects: 0
Study 38106904 — intervention group
Group type: EXPERIMENTAL
Intervention: Further research
Number of subjects: 0
Study 38107263 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351-containing induction 1 and 2 (Arm A)
Number of subjects: 0
Study 38107263 — intervention group
Group type: COMPARATOR
Intervention: Standard daunorubicin and dexrazoxane-containing induction (Arm B)
Number of subjects: 0
Study 38107263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early changes in sensitive echo indices (e.g., global longitudinal strain) and cardiac biomarkers (e.g., troponin and natriuretic peptides)
Number of subjects: 0
Study 38107263 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert consensus-based strategies in cardiac monitoring and anthracycline dose modification
Number of subjects: 0
Study 38107366 — intervention group
Group type: EXPERIMENTAL
Intervention: Short preoperative holistic risk factor screening questionnaire
Number of subjects: 560
Study 38107366 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain assessment using NRS and DN4
Number of subjects: 560
Study 38107366 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesic usage
Number of subjects: 560
Study 38107366 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being assessment using EQ-5D-5 L
Number of subjects: 560
Study 38107366 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial pain aspects assessment using HADs and STAI-trait
Number of subjects: 560
Study 38107366 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional pain inventory (MPI, part 1)
Number of subjects: 560
Study 38107443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a or peginterferon beta-1a therapy (IFN)
Number of subjects: 426
Study 38107482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg citrate supplementation
Number of subjects: 60
Study 38107482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 38107550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 75
Study 38107550 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 75
Study 38107641 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Chinese massage (TCM) - three weekly 25-min sessions
Number of subjects: 20
Study 38107641 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage sessions - three weekly 25-min sessions
Number of subjects: 20
Study 38107648 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Assisted digital biomarkers
Number of subjects: 400
Study 38107648 — intervention group
Group type: EXPERIMENTAL
Intervention: Established clinical assessments
Number of subjects: 400
Study 38107648 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health biomarkers from robotic or wearable sensing technology
Number of subjects: 400
Study 38107648 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Number of subjects: 400
Study 38107648 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative and qualitative measures
Number of subjects: 400
Study 38107755 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique for 4 weeks
Number of subjects: 148
Study 38107755 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 38107760 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation
Number of subjects: 42
Study 38107828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + letrozole
Number of subjects: 0
Study 38107828 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib + letrozole
Number of subjects: 0
Study 38107829 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (86.5%, 45/52)
Number of subjects: 314
Study 38107829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (83.3%, 40/48)
Number of subjects: 314
Study 38107829 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (62.5%, 25/40)
Number of subjects: 314
Study 38107829 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine alone
Number of subjects: 314
Study 38107829 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ER expression in metastasis
Number of subjects: 314
Study 38108112 — intervention group
Group type: EXPERIMENTAL
Intervention: NOSES VIIIA
Number of subjects: 352
Study 38108112 — intervention group
Group type: COMPARATOR
Intervention: Small-incision assisted right hemicolectomy
Number of subjects: 352
Study 38108208 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 46
Study 38108208 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 46
Study 38108208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 38108490 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pain ratings (mean 3.1 on a 10-point scale for Black participants)
Number of subjects: 879
Study 38108490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores at study enrollment
Number of subjects: 879
Study 38108490 — intervention group
Group type: EXPERIMENTAL
Intervention: Castration-resistant prostate cancer
Number of subjects: 879
Study 38108490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scales
Number of subjects: 879
Study 38108805 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC vaccination
Number of subjects: 7186
Study 38108805 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 7186
Study 38108805 — intervention group
Group type: COMPARATOR
Intervention: PCV7 vaccination
Number of subjects: 7186
Study 38108805 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCV13 period
Number of subjects: 7186
Study 38108805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib vaccination
Number of subjects: 7186
Study 38108805 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB ABM incidence
Number of subjects: 7186
Study 38108909 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-h fasting
Number of subjects: 28
Study 38108919 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 901
Study 38108919 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 901
Study 38108919 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 901
Study 38108961 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 850
Study 38108961 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 850
Study 38109034 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated, theatre-based intervention
Number of subjects: 47
Study 38109034 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 47
Study 38109117 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (target temperature 33 °C)
Number of subjects: 912
Study 38109117 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (target temperature 36.5 to 37.7 °C)
Number of subjects: 912
Study 38109170 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management programs including mental health education, physical activity content, and symptom management.
Number of subjects: 47
Study 38109170 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology as an aide to daily self-management.
Number of subjects: 47
Study 38109170 — intervention group
Group type: EXPERIMENTAL
Intervention: Customization or patient centeredness in web-based self-management programs.
Number of subjects: 47
Study 38109196 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPS+EIS
Number of subjects: 100
Study 38109196 — intervention group
Group type: COMPARATOR
Intervention: EIS-only
Number of subjects: 100
Study 38109197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 13
Study 38109282 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 0
Study 38109364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (nonabsorbable disaccharide)
Number of subjects: 0
Study 38109364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (antibiotic)
Number of subjects: 0
Study 38109364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal material transplantation (emerging therapeutic target)
Number of subjects: 0
Study 38109364 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 38109921 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2 vaccine administered at a 0.1 mL dose with a 1-week interval (group A)
Number of subjects: 905